Home
Anne Margrete Øyan's picture

Anne Margrete Øyan

Researcher
  • E-mailAnne.Oyan@uib.no
  • Phone+47 55 58 45 01
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2018. Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology. 94-101.
  • 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • 2018. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Pharmacology Research & Perspectives. 1-15.
  • 2017. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. BMC Cancer. 1-13.
  • 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • 2017. An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLOS ONE. 1-20.
  • 2016. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 15 pages.
  • 2016. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proceedings of the National Academy of Sciences of the United States of America. 9339-9344.
  • 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • 2015. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • 2015. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • 2014. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Molecular Cancer Research. 754-764.
  • 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • 2013. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLOS ONE. 12 pages.
  • 2013. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. International Journal of Cancer. 544-555.
  • 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 pages.
  • 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • 2013. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Research. 7090-7100.
  • 2013. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. 554-562.
  • 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • 2012. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 8699-8704.
  • 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • 2012. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 pages.
  • 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • 2012. Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation. BMC Cancer. 10 pages.
  • 2011. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 234-247.
  • 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • 2011. Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. American Journal of Pathology. 861-871.
  • 2011. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLOS ONE. 15 pages.
  • 2010. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 239-251.
  • 2010. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics. 15 pages.
  • 2009. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 575-582.
  • 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 53-68.
  • 2009. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 239-251.
  • 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 53-68.
  • 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • 2009. Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
  • 2009. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathology and Applied Neurobiology. 380-393.
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 pages.
  • 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer.
  • 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • 2008. Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. PLOS ONE.
  • 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • 2007. Increased expression of sim2-s protein is a novel marker of aggressive prostate cancer. Clinical Cancer Research. 892-897.
  • 2007. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. Journal of Neuro-Oncology. 191-202.
  • 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • 2007. ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • 2006. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 16466-16471.
  • 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • 2005. Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
  • 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 18-27.
  • 2004. Nucleosome binding by the bromodomain and PHD finger of the transcriptional cofactor p300. Journal of Molecular Biology. 773-788.
Popular scientific lecture
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer.
Academic lecture
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • 2006. ERG upregulation and related transcription factors in prostate cancer.
  • 2005. Discovering candidate genes that distinguish between CML and AML using microarrays.
  • 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • 2003. The PHD finger, a protein domain involved in chromatin-based gene regulation.
  • 2003. Global analysis of gene expression and regulatory patterns in acute myeloid leukemia.
  • 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
Reader opinion piece
  • 2010. Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Doctoral dissertation
  • 2018. Regulatory patterns in prostate cell differentiation – investigation of transcription factors AR, GATA2 and NKX3-1.
  • 1994. Infection by herpes simplex virus: a study of the interaction between virus ligands and the cellular receptors. (dr. scient).
Academic chapter/article/Conference paper
  • 2017. Models of Tumor Progression in Prostate Cancer. 16 pages.
Abstract
  • 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 pages.
  • 2011. TUMOR-ASSOCIATED GLIAL CELLS PROMOTE GROWTH OF GBM XENOGRAFTS IN EGFP NOD/SCID MICE. Neuro-Oncology. 55-55.
  • 2009. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 545-545.
  • 2007. Release of angiopoietin-1 by acute myelogenous leukemia (AML) cells is increased by stromal cells and associated with mutations in the nucleophosmin (NPM) gene. Experimental Hematology. 72-72.
  • 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Poster
  • 2013. TP63 regulation of EMT in an experimental prostate cell model.
  • 2013. Reactive oxygen species induce prostate cancer cells via activation of the IL6/STAT3 pathway. Abstract 304.
  • 2009. Suppression of heat shock Protein 27 induces long-term dormancy in human breast cancer.
  • 2009. Stepwise prostate carcinogenesis in vitro culture.
  • 2009. Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
  • 2009. Hyperoxic Treatment induces Mesenchymal-to-Epithelial Transition in a Rat Adenocarcinoma Model.
  • 2009. Highly infiltrative brain tumors show reduced chemosensitivity associated with a stem cell-like phenotype.
  • 2009. Global profiling of histone and DNA methylation reveals epigenetic-based gene regulation during EMT and transformation in a prostate cell model.
  • 2009. Global profiling of histone and DNA methylation reveals epigenetic-based gene regulation during EMT and transformation in a prostate cell model.
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • 2009. Epithelial to mesenchymal transition of a primary prostate cell line before malignant transformation with switches of cell adhesion modules.
  • 2009. A novel model of stepwise prostate carcinogenesis in culture.
  • 2008. Polycomb (PcG) targets are enriched in repressed genes in prostate cancer.
  • 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • 2007. Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo.
  • 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • 2006. Single-minded 2 homolog (SIM2) is overexpressed in prostate cancer.
  • 2006. Gene expression profiles identify an aggressive phenotype in endometrial carcinoma.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer.
  • 2005. Very high expression of specific transcription factors in prostate cancer compared with paired benign prostate tissue.
  • 2005. Single-minded 2 homolog gene (SIM2) is overexpressed in prostate cancer.
  • 2005. ETS transcription factors in prostate cancer.
  • 2005. Analysis of treatment response in acute myeloid leukemia patients using DNA microarrays.
  • 2003. The PHD finger of the transcriptional coactivator p300 binds nucleosomes in vitro.
  • 2002. The PHD finger: A protein domain involved in chromatin-based gene regulation.
Academic literature review
  • 2009. Tumor virology - history, status and future challenges. 382-399.
  • 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. 344-354.
  • 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. 741-751.

More information in national current research information system (CRIStin)